Spoken Alpha
SION
Sionna Therapeutics, Inc.
Overview
Sionna Therapeutics develops small-molecule medicines to treat cystic fibrosis by stabilizing the CFTR protein's nucleotide binding domain, targeting the F508del mutation that affects approximately 90% of CF patients.
Sionna Therapeutics, Inc is a Healthcare company operating in Biotechnology with a $174.7M market cap.
Most recent reported earnings: Q3 FY2026 (Nov 3, 2026).
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-10-04.
Transcripts
Recent earnings calls
No earnings calls indexed for SION yet
We index calls for roughly 3,000 US-listed companies. If you'd like us to add SION, reply to your welcome email and we'll prioritize it.
History
Earnings history
- Q3 FY20262026-11-03EPS— vs $-0.62—Rev— vs ——EODHD
- Q2 FY20262026-08-05EPS$-0.66 vs $-0.64-3.1%Rev$0 vs ——EODHD
- Q1 FY20262026-05-11EPS$-0.60 vs $-0.50-20.0%Rev$0 vs ——EODHD
- Q4 FY20252026-03-18EPS$-0.46 vs $-0.71+35.2%Rev$0 vs ——EODHD
- Q3 FY20252025-11-04EPS$-0.46 vs $-0.52+11.5%Rev$0 vs ——EODHD
- Q2 FY20252025-08-10EPS$-0.41 vs $-0.45+8.9%Rev$0 vs ——EODHD
- Q1 FY20252025-05-11EPS$-0.62 vs $-0.45-37.8%Rev$0 vs ——EODHD
- Q4 FY20242025-03-19EPS$-3.38 vs $-2.68-26.1%Rev$0 vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-03 | — | $-0.62 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-05 | $-0.66 | $-0.64 | -3.1% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-11 | $-0.60 | $-0.50 | -20.0% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-18 | $-0.46 | $-0.71 | +35.2% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-04 | $-0.46 | $-0.52 | +11.5% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-10 | $-0.41 | $-0.45 | +8.9% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-11 | $-0.62 | $-0.45 | -37.8% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-19 | $-3.38 | $-2.68 | -26.1% | $0 | — | — | EODHD |
Source: EODHD. SION reported actuals as published; sparse fields render as —.
Top executives
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
- Michael CloonanCEO1 yr 9 mono recorded callsCurrent
- Elena RidloffCFO10 mono recorded callsCurrent
- Caroline Stark BeerChief Business Officer1 yr 1 mono recorded callsCurrent
- Jennifer FitzpatrickChief Legal Officer1 yr 7 mono recorded callsCurrent
- Charlotte McKeeChief Medical Officer1 yr 9 mono recorded callsCurrent
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for SION.
$ curl https://api.spokenalpha.com/v1/companies/SIONFAQ
Frequently asked about SION
Where can I find Sionna Therapeutics, Inc.'s (SION) earnings call transcripts?
Spoken Alpha indexes SION's earnings call transcripts at https://spokenalpha.com/companies/SION. Each call links to attributed speakers and parsed analyst Q&A. Sionna Therapeutics, Inc.'s own investor relations page is at https://investors.sionnatx.com/.
What sector is SION in?
Sionna Therapeutics, Inc. (SION) operates in the Healthcare sector (Biotechnology industry).